Completed PHASE2 INTERVENTIONAL NCT00247572

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse

Sponsor: New River Pharmaceuticals

Conditions Amphetamine-Related Disorders Attention Deficit Disorder With Hyperactivity Substance-Related Disorders

Interventions NRP104

Updated 5 times since 2017 Last updated: Nov 1, 2007 Started: Sep 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Amphetamine-Related Disorders and Attention Deficit Disorder With Hyperactivity and is currently completed. New River Pharmaceuticals leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

New River Pharmaceuticals

Data source: New River Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States